Title
Increased doses lead to higher drug exposures of levofloxacin for treatment of tuberculosis
Date Issued
01 October 2018
Access level
open access
Resource Type
journal article
Author(s)
Peloquin C.A.
Phillips P.P.J.
Mitnick C.D.
Eisenach K.
Patienti R.F.
Lecc L.
Gandhi N.R.
Butler D.
Diacon A.H.
Santillan J.
Hunt K.R.
Von Groote-Bidlingmaier F.
Dianis N.
Moreno-Martinez A.
Kaur P.
Horsburgh C.R.
Publisher(s)
American Society for Microbiology
Abstract
Patients with multidrug-resistant tuberculosis in Peru and South Africa were randomized to a weight-banded nominal dose of 11, 14, 17, or 20 mg/kg/day levofloxacin (minimum, 750 mg) in combination with other secondline agents. A total of 101 patients were included in noncompartmental pharmacokinetic analyses. Respective median areas under the concentration-time curve from 0 to 24 h (AUC0-24) were 109.49, 97.86, 145.33, and 207.04 μg h/ml. Median maximum plasma concentration (Cmax) were 11.90, 12.02, 14.86, and 19.17 μg/ml, respectively. Higher levofloxacin doses, up to 1,500 mg daily, resulted in higher exposures. (This study has been registered at ClinicalTrials.gov under identifier NCT01918397.)
Volume
62
Issue
10
Language
English
OCDE Knowledge area
Farmacología, Farmacia Sistema respiratorio
Scopus EID
2-s2.0-85053940890
PubMed ID
Source
Antimicrobial Agents and Chemotherapy
ISSN of the container
00664804
Sources of information: Directorio de Producción Científica Scopus